Breast Cancer, Colorectal Cancer, Endometrial Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Stomach Cancer
Conditions
Brief summary
This is a multicenter, open-label, randomized, controlled study to test the hypothesis that ePRO monitoring added to usual care helps prolong OS or maintain and improve HRQoL in patients with unresectable advanced cancers or metastatic/recurrent solid tumors receiving systemic drug therapy.
Interventions
OTHERe-PRO monitoring
The e-PRO monitoring will concern treatment of each predefined type of cancer or characteristic symptoms of the condition. PRO-CTCAE (Patient-Reported Outcome-Common Terminology Criteria for Adverse Events) will be used as the scale for monitoring symptoms. The patient and (sub)investigator will share the monitoring results during examinations and use them to determine treatment strategies, etc. Threshold values will be predefined for a diagnosis of severe for individual symptoms. When it is reported that a threshold value has been exceeded, an alert notification will be sent to the study staff member assigned to the patient. The (sub)investigator who receives the notification will assess the information in the notification and take the best course of action.
Sponsors
Comprehensive Support Project for Oncology Research
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Unresectable, advanced, metastasized, or relapsed solid tumors (Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Stomach Cancer, Endometrial Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck) 2. Expected to be able to undergo treatment or observation for at least 6 months at the study site 3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or 2 4. Receiving systemic anticancer mono- or combination pharmacotherapy (e.g., cytotoxic anticancer agents, molecularly targeted drugs, and immune checkpoint inhibitors) at enrollment or scheduled to begin such therapy within 1 month from the date of enrollment (In principle, patients should be receiving pharmacotherapy on an out-patient basis.) 5. Capable of using electronic device (includes cases needing some assistance) 6. Aged 18 years or older at informed consent 7. Written consent for the study personally obtained from the subject
Exclusion criteria
1. Has undergone four or more regimens of pharmacotherapy for advanced, metastasized, or relapsed solid tumors\*Notes 1, 2 2. Currently participating in a study where PRO is tracked and the results are passed on to a physician 3. The following are
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) | After enrollment to death from any cause (up to 57 months) |
| HRQoL EORTC Quality of Life of Cancer Patients (QLQ-C30) global health status score | At enrollment and week 4,8,12,16,20 and 24 after enrollment |
Secondary
| Measure | Time frame |
|---|---|
| Quality-adjusted life year (QALY) score | After enrollment to death from any cause (up to 57 months) |
| At-home mortality rate | After enrollment to death from any cause (up to 57 months) |
| Time from last completion of drug therapy to death | Time from last completion of drug therapy to death from any cause (up to 57 months) |
| Number of unscheduled hospital visits during drug therapy | After enrollment up to 24 weeks |
| HRQoL EORTC Quality of Life of Cancer Patients (QLQ-C30) domain score | At enrollment and week 4,8,12,16,20 and 24 after enrollment |
| Total number of drug regiments | After enrollment up to 57 months |
| Incremental Cost-Effectiveness Ratio (ICER) | After enrollment up to 57 months |
| Communication between patients and healthcare providers (EORTC QLQ-COMU26 score) | At enrollment and week 24 after enrollment |
| Relative Dose Intensity (RDI) | After enrollment up to 24 weeks |
| HRQoL EQ-5D-5L index score | At enrollment and every 4 weeks after enrollment up to 57 months |
Countries
Japan
Outcome results
None listed